Effects of a Flaxseed-Derived Lignan Supplement in Type 2 Diabetic Patients: A Randomized, Double-Blind, Cross-Over Trial
2007

Flaxseed Lignan Supplement for Type 2 Diabetes

Sample size: 68 publication Evidence: moderate

Author Information

Author(s): Pan An, Sun Jianqin, Chen Yanqiu, Ye Xingwang, Li Huaixing, Yu Zhijie, Wang Yanfang, Gu Wenjia, Zhang Xinyi, Chen Xiafei, Demark-Wahnefried Wendy, Liu Yong, Lin Xu

Primary Institution: Key Laboratory of Systems Biology, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences

Hypothesis

The study aimed to investigate the effect of a flaxseed-derived lignan supplement on glycemic control, lipid profiles, and insulin sensitivity in type 2 diabetic patients.

Conclusion

Daily lignan supplementation resulted in modest, yet statistically significant improvements in glycemic control in type 2 diabetic patients without apparently affecting fasting glucose, lipid profiles, and insulin sensitivity.

Supporting Evidence

  • The lignan supplement significantly improved glycemic control as measured by HbA1c.
  • Urinary excretion of lignan metabolites was significantly higher after the lignan supplement intervention.
  • No significant changes were observed in fasting glucose and insulin concentrations.

Takeaway

This study tested a supplement made from flaxseed to see if it could help people with diabetes control their blood sugar better. It found that it did help a little bit, but not enough to make a big difference.

Methodology

This was a randomized, double-blind, placebo-controlled, cross-over trial conducted with 73 type 2 diabetic patients, where participants received either flaxseed-derived lignan capsules or a placebo for 12 weeks.

Limitations

The randomization was based on screening results rather than baseline measurements, and the modest changes in HbA1c may not be clinically sufficient.

Participant Demographics

Participants were type 2 diabetic patients aged 50-79 years, with a mix of genders and a majority taking oral hypoglycemic agents.

Statistical Information

P-Value

0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0001148

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication